A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH

Exclusion Criteria

• •Any subject with current, significant alcohol consumption or a history of significant alcohol consumption for a period of more than 3 consecutive months any time within 2 year prior to screening will be excluded
• •Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease
• •Uncontrolled diabetes mellitus as defined by a HbA1c ≥ 9.0％ at Screening
• •Patients who are allergic or hypersensitive to the drug or its constituents
• •Pregnant or lactating women